Interestingly, the lifespan of mice with Cockayne syndrome was prolonged and the severity of symptoms associated with PARP1 overactivation was reduced following treatment with PARP1 inhibitors or NAD+ supplementation [144]. The gene discussed is PARP1; the disease is Cockayne syndrome.